¿ Aronex Pharmaceuticals Inc., of The Woodlands, Texas, received a $6.3 million milestone payment from Abbott Laboratories, of Abbott Park, Ill., related to development of Nyotran, an injectable formulation of nystatin for systemic fungal infection. Since the November 1998 deal Aronex has received $17.7 million, including $3 million related to a stock purchase agreement.

¿ CoCensys Inc., of Irvine, Calif., said its board approved a 1-for-8 reverse stock split of common shares, effective April 15. After the split, the company will have about 4.3 million shares outstanding. The move is expected to head of the possibility of delisting from the Nasdaq market.

No Comments